OCUGEN
Ocugen is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to treat the whole eye. Our Phase 3 small molecule drug candidate for oGVHD, if approved, will be the first and only treatment for this orphan disease. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many”. And our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy.
OCUGEN
Social Links:
Industry:
Biopharma Biotechnology Health Care
Founded:
2013-01-01
Address:
Malvern, Pennsylvania, United States
Country:
United States
Website Url:
http://www.ocugen.com
Total Employee:
11+
Status:
Active
Contact:
(720)859-3549
Total Funding:
190 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Google Universal Analytics Domain Not Resolving
Similar Organizations
Nuvation Bio
Nuvation Bio is a biopharmaceutical company.
NuCana
NuCana is a clinical-stage biopharmaceutical company
Novaremed AG
Novaremed AG is a clinical-stage Swiss biopharmaceutical company.
Vidac Pharma
Vidac is a clinical stage innovative biopharmaceutical company dedicated to discovering
Vyriad
Vyriad is a clinical stage biopharmaceutical company.
Mereo Biopharma
Mereo is a new UK-based speciality biopharmaceutical company.
MatriSys Bioscience
MatriSys Bio is a clinical stage Specialty Biopharmaceutical Company.
Minerva Neuroscience
Minerva Neurosciences is a clinical-stage biopharmaceutical company
MetrioPharm
MetrioPharm is a clinical stage pharmaceutical development company.
Molecular Partners
Molecular Partners is a clinical-stage biopharmaceutical company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
MediPrint Ophthalmics
MediPrint Ophthalmics is a clinical stage eye care pharmaceutical company.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Acasti Pharma
Acasti Pharma is an emerging biopharmaceutical company.
Adrenomed
Adrenomed is a privately-financed, clinical-stage biopharmaceutical company.
Atom Bioscience & Pharmaceutical
Atom Bioscience is a clinical-stage biotechnology company.
Alpha Biopharma
Alpha Biophama is a clinical stage biopharmaceutical company.
Aniluxx Biotechnology
Aniluxx Biotechnology is a development stage biopharmaceutical company
Aurealis Pharma
Aurealis Pharma is a biopharmaceutical company.
Avitide
Avitide develops affinity purification solutions for biopharmaceutical companies.
Sio Gene Therapies
Sio Gene Therapies is a clinical-stage biopharmaceutical company.
Avalo Therapeutics
Avalo Therapeutics is a clinical-stage biopharmaceutical company.
Arbutus Biopharma
Arbutus Biopharma Corporation is a publicly-traded biopharmaceutical company.
Ascentage Pharma
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company.
EpimAb Biotherapeutics
EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company.
BlueRock Therapeutics
It is a regenerative medicine company.
Biocytogen
Biopharmaceutical company.
BirchBioMed
BirchBioMed is a clinical-stage biomedical company.
Bond Biosciences
Bond Biosciences is a biopharmaceutical company
BiondVax
BiondVax is an innovative biopharmaceutical company.
BioQ Pharma
BioQ Pharma is a late stage specialty pharmaceutical company focused on developing.
Frontier Biotechnologies
Frontier Biotechnologies is a commercial-stage bio-pharmaceutical company.
Transcode Therapeutics
TransCode Therapeutics is a pre-clinical biopharmaceutical company.
Touchlight Genetics
Touchlight Genetics, a British bio-pharmaceutical company founded in 2007.
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals is a clinical-stage biopharmaceutical company.
UroGen Pharma
UroGen Pharma is a clinical-stage biopharmaceutical company.
Kangpu Biopharmaceuticals, Ltd.
Kangpu Bio-Pharma is a clinical stage company.
SELLAS Life Sciences
SELLAS Life Sciences is a late-stage biopharmaceutical company.
Strekin
Strekin AG is a clinical-stage biopharmaceutical company headquartered in Basel, Switzerland.
SAB Biotherapeutics
SAB Biotherapeutics is a clinical-stage biopharmaceutical development company.
SciClone Pharmaceuticals
SciClone Pharmaceuticals is a pharmaceutical company.
Soleno Therapeutics
Soleno Therapeutics is a clinical-stage biopharmaceutical company.
Semler Scientific
Semler Scientific is an emerging medical risk-assessment company.
Samsung Bioepis
Samsung Bioepis is a biopharmaceutical company.
Akashi Therapeutics
Akashi Therapeutics is a clinical stage biopharmaceutical company.
Destiny Pharma
Destiny Pharma Ltd., a clinical stage pharmaceutical company
Hope Medicine
Hope Medicine is a science-driven clinical stage biopharmaceutical company
Humanetics Corporation
clinical stage pharmaceutical company.
HUTCHMED (China) Limited
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company.
Inversago Pharma
Inversago Pharma is a specialized, preclinical-stage biotech company.
ImmunoBrain Checkpoint
ImmunoBrain Checkpoint is a biopharmaceutical company.
IconOVir Bio
IconOVir Bio is a preclinical-stage biotechnology company.
GENFIT
GENFIT is a late-stage biopharmaceutical company.
Giiant Pharma
Giiant Pharma is a preclinical-stage biotech company.
Oxeia Biopharmaceuticals
Oxeia Biopharmaceuticals is a clinical stage biotech company.
OncoQuest
OncoQuest is a Edmonton-based biopharmaceutical company.
Ovid Therapeutics
Ovid Therapeutic's purpose is to solve intractable medical problems.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
ORIC Pharmaceuticals
ORIC Pharmaceuticals operates as a biopharmaceutical company.
Opiant Pharmaceuticals
Opiant Pharmaceuticals is a specialty pharmaceutical company.
Cellenkos
Cellenkos is a clinical stage biotech company.
Calimmune
Calimmune is a clinical-stage gene therapy company.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company.
Cassava Sciences
Cassava Sciences is a clinical-stage biopharmaceutical company focused on neuroscience.
CytoVac
Cytovac is a clinical-stage biopharmaceutical company.
Caladrius Biosciences
Caladrius Biosciences is a clinical-stage biopharmaceutical company.
Peptidream
Peptidream is a biopharmaceutical company.
PharmaIN
PharmaIN is a development stage biopharmaceutical company,
PlasmaGen Biosciences
PlasmaGen Biosciences is a biopharmaceutical company .
Yisheng Biopharma
Yisheng Biopharma is a global, fully integrated bio-pharmaceutical company.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
Date | Company | Article | Price |
---|---|---|---|
2019-09-30 | Histogenics | Histogenics acquired by Ocugen | N/A |
Investors List
ROTH Capital Partners
ROTH Capital Partners investment in Post-IPO Equity - Ocugen
Abdi Ibrahim Pharmaceuticals
Abdi Ibrahim Pharmaceuticals investment in Series B - Ocugen
Lancaster Group
Lancaster Group investment in Series B - Ocugen
Frank Leo
Frank Leo investment in Series B - Ocugen
John Zhang
John Zhang investment in Series B - Ocugen
Bernhard Hampl
Bernhard Hampl investment in Series A - Ocugen
Ahsan M. Nasratullah
Ahsan M. Nasratullah investment in Series A - Ocugen
EB5 Life Sciences
EB5 Life Sciences investment in Series A - Ocugen
Key Employee Changes
Date | New article |
---|---|
2022-09-01 | Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer |
Official Site Inspections
http://www.ocugen.com Semrush global rank: 1.75 M Semrush visits lastest month: 13.48 K
- Host name: 68.121.245.35.bc.googleusercontent.com
- IP address: 35.245.121.68
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Ocugen" on Search Engine
Ocugen Inc. - Patient-Centric Biotechnology
A fully integrated, patient-centric biotech company focused on vaccines in support of public health and gene and cell therapies targeting unmet medical needs through Courageous Innovation.See details»
About - Ocugen
Ocugen. OUR PEOPLE. Our leaders have a proven track record of success across the healthcare industry—in biopharmaceutical research, commercialization, medicine, and operations. They bring their individual experiences, in the public sector and private industry, to the collective work we are doing to benefit patients.See details»
Our People - Ocugen
Dr. Musunuri is a seasoned biotech veteran with about 30+ years of results-driven experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, Dr. Musunuri held leadership roles at numerous companies ranging from “Big Pharma” to novel start-up biotechs.See details»
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment …
Apr 8, 2024 Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe.See details»
Ocugen - Crunchbase Company Profile & Funding
Ocugen is a biotechnology company that develops novel gene and cell therapies to improve health and patient outcomes. Malvern, Pennsylvania, United States. 51-100. Post-IPO Equity. Public. ocugen.com. 6,314. Highlights. Stock Symbol NASDAQ:OCGN. Acquisitions 1. Total Funding Amount. Unlock for free. Contacts 73. Employee Profiles 9. …See details»
Ocugen, Inc. Announces Dosing Completion of Subjects with …
Mar 13, 2024 Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe.See details»
Ocugen Provides Business Update with Fourth Quarter and Full …
MALVERN, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today reported fourth quarter and full year 2022 financial results along with a general …See details»
Therapeutic Areas - Ocugen
Ocugen’s focus centers on finding ways to make hard-to-treat blindness diseases a thing of the past. Below are areas our researchers and collaborators are exploring to help people and families with a hopeless prognosis. Asset/ Program. OCU400. AAV-hNR2E3. Received orphan drug designations. Indication.See details»
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2
Apr 1, 2022 Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines that improve health and offer hope for people and...See details»
UPDATE -- Ocugen to Present on Modifier Gene Therapy …
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...See details»
Press Releases | Ocugen, Inc.
May 10, 2024 April 26, 2024. Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy.See details»
Ocugen Announces OCU400—Modifier Gene Therapy—Phase …
Apr 29, 2024 OCU400 is the Company’s gene-agnostic modifier gene therapy product based on NHR gene, NR2E3 . NR2E3 regulates diverse physiological functions within the retina—such as photoreceptor development and maintenance, metabolism, phototransduction, inflammation and cell survival networks.See details»
Events and Presentations | Ocugen, Inc.
Apr 2, 2024 Ocugen, Inc. First Quarter 2024 Financial Results and Recent Business Highlights.See details»
Biologicals - Ocugen
Gene Therapies. Biologicals. OCU200 is a biologic product candidate in preclinical development for treating severely sight-threatening diseases like Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), and Wet Age …See details»
Ocugen Announces CSO to Present on Modifier Gene Therapy at ...
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...See details»
Traditional gene therapies are uber-niche. Ocugen hopes to …
Apr 15, 2024 But a Pennsylvania-based biotech company Ocugen is hoping to change that paradigm by working on therapies that it calls “gene agnostic,” using a first-in-class modifier gene therapy platform with the potential to treat a range of genetically diverse inherited retinal diseases.See details»
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention …
Jun 30, 2023 Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe.See details»
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment …
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel...See details»
Ocugen Clinical Trial Could Lead to Breakthrough One-Time …
Dec 19, 2023 OCU410 is a potential curative therapy, administered with a single sub-retinal injection, that modulates hundreds of genes and multiple pathways that are involved in dry AMD, including lipid metabolism, inflammation, …See details»
Patients - Ocugen
Home. Patients. OUR COMMITMENT. We’re inspired by the opportunity – and the responsibility – to develop therapies with the potential to improve health, offer hope, and even change the lives of patients. They deserve better. They deserve our best.See details»